Durect: Indivior reported FDA approval of NDA for schizophrenia med

DURECT announced that Indivior has reported that the FDA has approved the New Drug Application, or NDA, for PERSERIS, which was formerly known as RBP-7000. As described by Indivior, PERSERIS is the first once-monthly subcutaneous risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults.

https://bit.ly/2vlspGm